Type of security: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
The data is delayed by 15 minutes.
Description: Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company?s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement
|Shares Outstanding||EPS||1.04||EPS Growth - 4 Quarters||-41.96%||EPS Growth - Q/Q||-77.94%|
|EPS Growth - Y/Y||41.76%||Sales Growth - 4 Quarters||-13.81%||Sales Growth - Q/Q||-15.83%||P/E||55.7|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||9.54%||ROE||32.67%||ROI||12.64%|
|Current Ratio||1.6||Quick Ratio||1.03||Long Term Debt/Equity||2.1||Debt Ratio||0.84|
|Gross Margin||48.63%||Operating Margin||15.2%||Net Profit Margin||14.29%||Dividend Payout Ratio||-46.86%|
|Cash From Financing Activities||384 M||Cash From Investing Activities||-770 M||Cash From Operating Activities||96 M||Gross Profit||1.92 B|
|Net Profit||332 M||Operating Profit||435 M||Total Assets||24.86 B||Total Current Assets||9.73 B|
|Total Current Liabilities||6.07 B||Total Debt||10.01 B||Total Liabilities||17.6 B||Total Revenue||3.89 B|
|High 52 week||81.77||Low 52 week||61.23||Last close||74.33||Last change||-0.08%|
|RSI||14.09||Average true range||1.4||Beta||0.58||Volume||1.84 M|
|Simple moving average 20 days||-6.16%||Simple moving average 50 days||-2.81%||Simple moving average 200 days||3.66%|
|Performance Week||-6.89%||Performance Month||-3.69%||Performance Quart||7.81%||Performance Half||3.87%|
|Performance Year||11.16%||Performance Year-to-date||13.22%||Volatility daily||1.38%||Volatility weekly||3.08%|
|Volatility monthly||6.32%||Volatility yearly||21.9%||Relative Volume||171.45%||Average Volume||2.88 M|
|New High||New Low|
2019-04-17 14:31:37 | Why Qualcomm Is among Steve Cohen’s Top Bets
2019-04-16 16:15:00 | Baxter to Present at the Bank of America Merrill Lynch Health Care Conference 2019
2019-04-16 07:33:43 | How Baxter International Inc. NYSE:BAX Could Add Value To Your Portfolio
2019-04-15 08:15:44 | The Future Keeps Looking Better and Better for BAX Stock
2019-04-09 08:30:00 | Baxter Unveils the Latest Evolution of Floseal at AORN Meeting
2019-04-04 16:30:00 | Baxter to Host Webcast of Annual Meeting of Stockholders
2019-04-03 00:42:37 | Here is What Third Point Thinks About Baxter International Inc. BAX
2019-04-02 11:48:48 | See what the IHS Markit Score report has to say about Baxter International Inc.
2019-04-01 10:12:56 | Is Baxter International Inc.’s NYSE:BAX 14% ROCE Any Good?
2019-03-28 10:53:37 | Here is What Hedge Funds Think About Baxter International Inc. BAX Right Now
2019-03-28 09:54:01 | Baxter Showcases PN Product Portfolio at ASPEN Conference
2019-03-27 08:49:12 | Moving Average Crossover Alert: Baxter International
2019-03-26 16:35:00 | Baxter Highlights Advancements in Clinical Nutrition at ASPEN Conference
2019-03-26 06:00:00 | 3 Large-Cap Stocks Hitting 52-Week Highs: Are They Buys?
2019-03-25 08:37:12 | Fresenius Medical's New Hemodialysis Software Gets FDA Nod
2019-03-22 09:35:01 | Baxter BAX Soars to 52-Week High, Time to Cash Out?
2019-03-21 18:13:30 | MS Global Franchise Fund's Top 5 Buys of the 4th Quarter
2019-03-21 07:51:11 | Moving Average Crossover Alert: Baxter International
2019-03-19 14:31:06 | Top Analyst Reports for Home Depot, Oracle & Union Pacific
2019-03-19 12:08:04 | Baxter BAX Upgraded to Buy: Here's What You Should Know
2019-03-19 10:41:02 | Baxter's BAX New Tie Up to Boost Acute Therapies Business
2019-03-12 10:24:41 | See what the IHS Markit Score report has to say about Baxter International Inc.
2019-03-07 08:33:01 | Baxter BAX Gets FDA Approval for Eptifibatide to Treat ACS
2019-03-06 08:00:28 | See what the IHS Markit Score report has to say about Baxter International Inc.
2019-03-06 07:15:00 | Analysis: Positioning to Benefit within XPO Logistics, L3 Technologies, Domino's Pizza, Baxter International, Conduent, and Xylem — Research Highlights Growth, Revenue, and Consolidated Results
2019-03-02 08:49:07 | If You Had Bought Baxter International Shares Three Years Ago You’d Have Made 89%
2019-02-28 17:50:02 | Dan Loeb’s Third Point Looks to Baxter and Campbell Soup in 2019
2019-02-22 16:11:39 | Daniel Loeb Comments on Baxter
2019-02-22 13:01:07 | U.S. closes IV solution shortage antitrust probe, Baxter says
2019-02-21 18:48:19 | Baxter International Inc BAX Files 10-K for the Fiscal Year Ended on December 31, 2018
2019-02-19 08:45:00 | Baxter Declares Quarterly Dividend
2019-02-16 08:40:36 | Does Baxter International Inc. NYSE:BAX Have A Good P/E Ratio?
2019-02-14 09:07:02 | Baxter's Acute Therapies Profile Strong, Competition Rife
2019-02-13 16:15:00 | Baxter to Present at the Barclays Global Healthcare Conference
2019-02-12 08:54:10 | Dan Loeb Increased Third Point’s Position in These Stocks in Q4
2019-02-06 16:15:00 | Baxter to Present at the Raymond James 40th Annual Institutional Investors Conference
2019-02-05 10:30:02 | What Are Abbott Laboratories’ Key Growth Drivers in 2019?
2019-02-04 18:02:02 | [$$] Blood-Pressure Medicine Will Be First Product for New Generic Drug Venture
2019-02-04 07:25:00 | Report: Developing Opportunities within Ensco plc, Third Point Reinsurance, Baxter International, Ultrapar Participacoes S.A, Endeavour Silver, and Ingles Markets — Future Expectations, Projections Moving into 2019
2019-01-31 17:53:14 | Baxter BAX Q4 2018 Earnings Conference Call Transcript
2019-01-31 17:14:43 | Edited Transcript of BAX earnings conference call or presentation 31-Jan-19 1:30pm GMT
2019-01-31 11:42:04 | Baxter's BAX Earnings, Revenues Beat Estimates in Q4